Skip to Content

Dacogen (decitabine) Disease Interactions

There are 3 disease interactions with Dacogen (decitabine):

Moderate

Decitabine (applies to Dacogen) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

There are no data on the use of decitabine in patients with hepatic dysfunction. Decitabine should be used with caution in these patients.

Moderate

Decitabine (applies to Dacogen) hematological toxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thrombocytopenia, Neutropenia

Treatment with decitabine is associated with neutropenia and thrombocytopenia. It is recommended to consider the need for early institution of growth factors and/or antimicrobial agents for the prevention or treatment of infections in patients with myelodysplastic syndromes (MDS). Complete blood and platelet counts should be performed as needed to monitor response and toxicity, but at a minimum, before each dosing cycle. After administration of the recommended dosage for the first cycle, treatment for subsequent cycles should be adjusted according to manufacturer recommendations. Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles and may not necessarily indicate progression of underlying MDS. Closely monitor patients at risk for hematological toxicities.

Moderate

Decitabine (applies to Dacogen) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

There are no data on the use of decitabine in patients with renal dysfunction. Decitabine should be used with caution in these patients.

Dacogen (decitabine) drug interactions

There are 162 drug interactions with Dacogen (decitabine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.